Effects of Angiotensin 2 Type 1 Receptor Antagonist, Losartan, on Ventilatory Response to Exercise and Neurohormonal Profiles in Patients with Chronic Heart Failure

DOI Web Site PubMed 参考文献60件
  • Kinugawa Toru
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine
  • Kato Masahiko
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine
  • Ogino Kazuhide
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine
  • Osaki Shuichi
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine
  • Igawa Osamu
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine
  • Hisatome Ichiro
    Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
  • Shigemasa Chiaki
    Department of Cariovascular Medicine, Tottori University Faculty of Medicine

書誌事項

タイトル別名
  • Effects of Angiotensin II Type 1 Receptor Antagonist, Losartan, on Ventilatory Response to Exercise and Neurohormonal Profiles in Patients with Chronic Heart Failure

この論文をさがす

抄録

Chronic heart failure (CHF) is associated with abnormal neurohormonal profiles and increased ventilatory response to exercise. This study determined if treatment with angiotensin II type 1 receptor antagonist, losartan, improves ventilatory efficiency and neurohormonal factors in patients with CHF. Symptom-limited cardiopulmonary exercise testing was performed after a 2-week placebo period (baseline) and after 16 weeks of treatment with losartan (40 ± 4 mg/day) in 10 patients with CHF (age 57.7 ± 3.7 years). Echocardiogram, daily physical activity (by the specific activity scale), and neurohormones were evaluated. Treatment with losartan increased left ventricular ejection fraction (baseline vs. losartan: 31 ± 3 vs. 39 ± 3%, p < 0.01) and specific activity scale score (5.3 ± 0.5 vs. 6.4 ± 0.4 METS, p < 0.05). Losartan decreased the ventilatory response to carbon dioxide production during exercise (VE/VCO2 slope: 34.6 ± 2.4 vs. 32.0 ± 2.2, p < 0.05). Plasma brain natriuretic peptide concentrations were decreased after therapy (301 ± 79 vs. 176 ± 53 pg/ml, p < 0.05). In summary, the results of this open-label, uncontrolled study suggest that chronic treatment with losartan may improve ventilatory efficiency and decrease plasma brain natriuretic peptide concentrations with the improvement of physical activity and left ventricular systolic function in patients with CHF.<br>

収録刊行物

参考文献 (60)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ